Compare abrdn Income Credit Strategies Fund (ACP) vs Axogen Inc (AXGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Axogen Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Axogen Inc trades at $43.17 (market cap $2.37B). The key difference: Axogen Inc is far larger — about 3.6× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| ACP | AXGN | |
|---|---|---|
Market Cap | $656.21M | $2.37B |
Sector | Financials | Technology |
52-Week High | $5.98 | $46.19 |
52-Week Low | $5.01 | $11.28 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $2.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
AXGN trades at $45.97, up 0.17% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 earnings of $0.07 per share, missing estimates, yet maintains a strong gross margin of 75.01%. Recent news highlights a bullish rebound and raised 2026 guidance, with 84% of analysts rating it a Buy. Support is at $44, with resistance at $47.
Outlook is cautiously optimistic due to strong analyst support and recent institutional interest, but risks include consecutive earnings misses and negative net income margins. The consensus price target of $47.60 suggests modest upside, though execution on guidance and reimbursement wins are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
